Jeil Pharmaceutical Co Ltd

Jeil Pharmaceutical's capital structure shows a debt-to-equity ratio of 0.55, indicating moderate leverage relative to its equity base. The company's liquidity position is assessed as medium, with a current ratio of 0.99, suggesting it is nearly balanced in its ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics are weak, with a return on equity (ROE) of -1.86% and a return on assets (ROA) of -0.59%, both significantly below the industry median for pharmaceutical firms. These negative returns suggest the company is underperforming in generating returns for shareholders and asset utilization.

The company's revenue is concentrated in a single geographic market, South Korea, with no disclosed international revenue streams. This lack of geographic diversification increases exposure to local regulatory, economic, and competitive pressures. No segment-specific revenue breakdown is available, but the absence of disclosed segments implies a lack of diversification in product lines or therapeutic areas.

Looking ahead, the company is expected to face continued financial pressure, with no clear signs of improvement in operating income or net income. The operating cash flow of 546 million KRW is insufficient to cover capital expenditures of 1.9 billion KRW, leading to a negative free cash flow of 2.5 billion KRW. This suggests the company is not generating enough cash to sustain operations without external financing or asset sales.

The risk assessment highlights liquidity concerns, with a negative net cash position after debt. While dilution risk is currently low, the company's negative free cash flow and operating losses may necessitate future equity or debt financing, which could increase dilution risk. No recent filings or transcripts have been disclosed that provide insight into strategic changes or operational improvements.

Net income surged 178% year-over-year to 23.4 billion KRW, signaling a strong operational turnaround.

Free cash flow improved by 254.2% to 37.2 billion KRW, demonstrating significantly enhanced cash generation capabilities.

Operating income jumped 207.4% to 20.7 billion KRW, indicating substantial improvement in core business profitability.

Long-term debt decreased to 93.4 billion KRW, reflecting a deliberate strategy to reduce financial leverage.

Gross profit remained robust at 212.9 billion KRW, maintaining a healthy margin despite revenue fluctuations.

The company faces high credit risk, posing potential challenges for future financing and operational stability.

Cash conversion ratio of -0.19 places the company in the bottom quartile of its pharmaceutical cohort.